Lv1
70 积分 2024-10-15 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
26天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
Corneal Changes From Antibody-Drug Conjugates
1个月前
已完结
Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis
1个月前
已完结
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies
3个月前
已完结
皖公网安备34019202002308
